Effects of Peroxisome Proliferator-Activated Receptor-Gamma Activation With Pioglitazone on Plasma Adipokines in Nondiabetic Patients With Either Hypercholesterolemia or Hypertension

Association of Resistin With Urinary Albumin Excretion in Nondiabetic Patients With Essential Hypertension

“…17 This discrepancy might be due to the absence of any treatment in our population, in contrast to others, [12][13][14]17 that renders it ideal to assess the link of albuminuria with resistin, due to the fact that diverse therapies (i.e., angiotensin receptor blockers, calcium channel blockers, and thiazolidinediones) significantly influence resistin levels in clinical and experimental settings. [24][25][26] Increased ACR in hypertensive subjects can be considered a consequence of preglomerular microvasculopathy, 16,27 or might be a result of eGFR decline. 16,17,26,27 However, in our study, the differences in ACR between resistin groups as well as the interrelationship between urinary albumin excretion and resistin was not influenced significantly by levels of eGFR.…”

“…[24][25][26] Increased ACR in hypertensive subjects can be considered a consequence of preglomerular microvasculopathy, 16,27 or might be a result of eGFR decline. 16,17,26,27 However, in our study, the differences in ACR between resistin groups as well as the interrelationship between urinary albumin excretion and resistin was not influenced significantly by levels of eGFR. In this context, resistin may augment the expression of endothelin, adhesion molecules, matrix metalloproteinases, promoting systemic vascular dysfunction and affecting unfavorably albuminuria levels.…”

Weight gain by hyperalimentation elevates C-reactive protein levels but does not affect circulating levels of adiponectin or resistin in healthy subjects

“…The clinical correlates of levels of adipokines are corroborated by the finding that the circulating levels of resistin in humans are lowered by treatment with the anti-diabetic insulin-sensitizing PPARG agonist drugs rosiglitazone and pioglitazone, while such treatment concomitantly increases the levels of adiponectin (15)(16)(17).…”

PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty

“…TZD PPAR-␥ activators are the most effective class of approved drugs to raise circulating adiponectin concentrations. In patients with type 2 diabetes or other insulin-resistant conditions, TZD treatment typically produces a doubling of plasma adiponectin concentration ( 17,(73)(74)(75). In contrast, other antidiabetic or lipid-modifying drugs produce much smaller or no changes in adiponectin (76)(77)(78)(79).…”

“…In patients with type 2 diabetes or other insulin-resistant states, TZD treatment improves brachial artery endothelial function, as marked by greater fl ow or acetylcholine-mediated vasodilation ( 75,(110)(111)(112). Improvements in coronary endothelium-dependent vasodilation have been demonstrated with pioglitazone ( 113,114 ).…”